Callan JMB Inc. - SIC # 2642 -

Ticker Exchange SIC # Website Latest Ticker
CJMB Nasdaq 2642 callanjmb.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Callan JMB Inc.

Callan JMB, Bia Power Systems and Alabama State University Announce $60 Million Advanced Electrical Manufacturing Venture in Brewton, Alabama - Aug 11th, 2026 6:00 am
Callan JMB Announces Formation of Callan Power to Advance Domestic Manufacturing of Critical Electrical Infrastructure - Aug 6th, 2026 6:00 am
Callan JMB Expands Atlas Complex, Advances Recurring Infrastructure Services Business with Cavalry 1838 Equine Biosciences - Aug 4th, 2026 6:00 am
Callan JMB and Alabama State University Break Ground on Atlas Complex, Launching an Unprecedented Strategic Partnership to Advance U.S. Pharmaceutical Manufacturing and Supply Chain Resilience - Jul 29th, 2026 7:00 am
Callan JMB and Alabama State University Announce Strategic Partnership to Advance U.S. Pharmaceutical Manufacturing and Supply Chain Resilience - Jul 16th, 2026 6:00 am
Callan JMB Inc. and Alabama State University Partner to Advance Workforce Development, Research, and Pharmaceutical Innovation at the Atlas Complex - Jul 8th, 2026 3:05 pm
Callan JMB Expands Oregon Public Health Support Capabilities Through State VFC Authorization - Jun 11th, 2026 6:45 am
Insiders Give Up US$84k As Callan JMB Stock Drops To US$0.79 - May 24th, 2026 6:31 am
Callan JMB Expands Long-Standing Public Sector Infrastructure Engagement - May 20th, 2026 7:00 am
Callan JMB Launches The Atlas Complex in Alabama to Successfully Achieve the Capture of Significant Pharmaceutical Onshoring Demand and Expand U.S. Supply Chain Infrastructure - Apr 20th, 2026 6:00 am
Callan JMB Issues Statement on Recently Filed Lawsuit by Eddie Patent Holdings LLC - Apr 17th, 2026 3:00 pm
Callan JMB Successfully Deploys Rapid Redistribution of Critical Pharmaceuticals to Combat Localized Disease Outbreaks for Longstanding Customer - Apr 7th, 2026 6:45 am
Callan JMB Reports Full Year 2025 Financial Results and Provides Business Update - Mar 31st, 2026 2:05 pm
Callan JMB Supports U.S. Scale-Up of Multi-Indication Immune Platform with Phase 2b/3 Advancement - Mar 27th, 2026 6:45 am
DifGen Pharmaceuticals and Aveva Drug Delivery Systems Lead U.S. Technology Transfer and Platform Development Collaboration for Multi-Indication Immune Restoration Therapy with Active IND Programs and Phase 2b/3 Authorization in PASC - Mar 25th, 2026 6:37 am
Callan JMB Inc. to Oversee Manufacturing and Quality Control of Attune Biotech’s IND Clinical Trials for lodonal™ in the Treatment of Long COVID - Mar 11th, 2026 6:45 am
Updated Lineup Announced for the iAccess Alpha Virtual Best Ideas Spring Investment Conference March 10-11, 2026 - Mar 10th, 2026 7:00 am
iAccess Alpha Virtual Best Ideas Spring Investment Conference March 10–11, 2026 - Mar 4th, 2026 7:00 am
Callan JMB CEO, Wayne Williams Invited to Attend the 50th International GMP Conference on March 2-5, 2026 - Mar 2nd, 2026 6:45 am
Callan JMB Announces Participation in the iAccess Alpha Virtual Best Ideas Spring Investment Conference on March 10–11, 2026 - Feb 27th, 2026 6:45 am